Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, ...

Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...

The prevalence of obesity continues to remain high in the US making the demand for effective treatments even more urgent.

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Wall Street stocks turned in a mixed performance on Monday as Q3 earnings season gets set to pick up steam. At the close, the ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $383.00. Yaron ...

The Global Pancreatic Cancer Industry, projecting a valuation of approximately US$ 2,125.57 Million by the end of 2023. The ...

nVerses Capital LLC grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 800.0% in the 3rd quarter, according to the ...